TAVR and Surgery Outcomes Similar at 5 Years

In patients with severe aortic stenosis and intermediate surgical risk, major clinical outcomes were similar after TAVR and surgery.

Although transcatheter aortic valve replacement (TAVR) is now the predominant treatment for patients with severe, symptomatic aortic stenosis, there are few data comparing long-term outcomes of TAVR versus surgery. A manufacturer-funded, randomized study comparing a self-expanding TAVR prosthesis with surgery in 1660 patients at intermediate surgical risk demonstrated similar outcomes at 2 years (NEJM JW Cardiol May 2017 and N Engl J Med 2017; 376:1321). Now, the investigators report the 5-year outcomes of this trial.

The mean age of patients was 80 years, 44% were women, and the mean Society of Thoracic Surgery Predicted Risk of Mortality score was 4.5%. Patients underwent procedures between 2012 and 2016, and most TAVR patients (84%) recei…

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI

Leadership Positions in Professional SocietiesHeart Valve Collaboratory (Scientific Committee Member, Chair of the Publications Committee)